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Introduction
We aimed to evaluate the clinical, biological and viro-
logical impact of antiviral therapy in severe acute
hepatitis B. [1]
Materials and methods
We performed a study in the National Institute for
Infectious Diseases “Prof. Dr. Matei Bals”, Bucharest,
Romania, randomizing patients between two groups
initially: therapy with lamivudine 100 mg/day vs. stan-
dard of care (no antiviral therapy) and subsequently
between three groups: lamivudine, standard of care and
entecavir 0.5 mg/day, when this new analogue became
available in Romania.
Results
HBs antigen to antibody seroconversion was recorded by
24 weeks in 10.1% of the patients in the lamivudine
group (p=0.032 compared to control), 42.9% of those in
the entecavir group (p=0.053 compared to control), and
22.7% in the control (standard of care) group.
Conclusions
If antiviral therapy is to be considered in severe acute
hepatitis B, entecavir could be regarded as an option, as
it might increase the chance of HBs antigen to antibody
seroconversion when administered in the first 24 weeks
of infection. [2,3] However, further studies are required
to ascertain this, and to eventually determine the magni-
tude of the effect.
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